Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01749410 · ClinicalTrials.gov registry record
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 33
- Enrollment target
NCT01749410 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 33 participants.
The verdict
NCT01749410 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
Interventions
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01749410
The ClinicalTrials.gov registry entry for NCT01749410 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT01749410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01749410 about?
NCT01749410 is a clinical study titled "A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines". This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
What is the current status of trial NCT01749410?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2013-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01749410?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT01749410?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.